Dr. Runa Acharya, MD

Dr. Acharya practices at Roswell Park Cancer Institute in Los Angeles, California.

Dr. Acharya's NPI, 1477817401, was assigned on June 25, 2012. Dr. Acharya graduated from University of Nebraska College of Medicine in 2012. Dr. Acharya holds New York license 288224.

Dr. Acharya's primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Dr. Acharya's primary practice is Roswell Park Cancer Institute in Los Angeles, California. Dr. Acharya is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is Roswell Park Comprehensive Cancer Center. Dmand AI also links Dr. Acharya to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Acharya practices, 2 sites in all. Vendor and product names are available with a free account.

Endocrinology, diabetes and metabolism is Dr. Acharya's primary specialty in the NPI Registry, under taxonomy code 207RE0101X. Dmand AI has Dr. Acharya's licenses on file in 2 states: New York and Iowa.

CMS data shows 240 Medicare services from Dr. Acharya across 5 procedure codes in 2024, for 199 Medicare patients. Medicare paid $17,918 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 199 Medicare patients who saw Dr. Acharya in 2024. The largest group is 65 to 74, with 80 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 29% are also on Medicaid. Their average risk score is 2.49, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Acharya's median patient age at 65, with 70% women.

In 2024, Dr. Acharya wrote 728 Medicare Part D claims for 158 patients. 40% of them were for generic drugs. CMS names the drug for 486 of them, across 17 drugs with 11 or more claims each, at $308,344 in total drug cost. In 2023, CMS named 241 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Acharya for performance year 2024, reported as part of a group. Dr. Acharya accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Acharya as offering telehealth.

Dmand AI links 8 papers to Dr. Acharya, published from 2017 to 2024. The most frequent topics are Adrenal Glands, Diabetic Ketoacidosis and Hyperparathyroidism, Primary. Dr. Acharya has published most often in J Clin Endocrinol Metab. Dr. Acharya's most frequent co-authors are Mashaal Dhir, MBBS, Grazia M. Aleppo, MD and Leen Alkukhun, MD.

CMS Open Payments shows 10 general payments to Dr. Acharya from 6 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $133.

Dr. Acharya graduated from University of Nebraska College of Medicine in 2012.